Kite Pharma, Inc. has received $-1.76 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 8 Financial Advisor in the Stock Trading Firms. Among 8 Analysts, Bottom line EPS Estimate for the current quarter is $-2.01 while the top line estimate is $-1.52 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -106.91%.
Kite Pharma, Inc. reported better than expected with a surprise EPS of 11.31% or $0.19 during its most recent quarterly earnings. The Actual EPS was $-1.49 compared to the Estimated EPS of $-1.68.
In the last quarter, Kite Pharma, Inc. reported Annual Earnings of $-1.49. Based on the filings, last years Annual Earnings was, $-2.33. In the last Quarter, KITE reported a surprise Earnings per Share of 11.31% . The consensus estimate for current quarter is $-1.76 and for the current fiscal year, the estimate is $-5.48. For the Next fiscal year, the estimate is $-6.85 based on the consensus.
Kite Pharma, Inc. (NASDAQ:KITE) : On Tuesday heightened volatility was witnessed in Kite Pharma, Inc. (NASDAQ:KITE) which led to swings in the share price. The stock opened for trading at $48.88 and hit $51 on the upside , eventually ending the session at $50.97, with a gain of 4.58% or 2.23 points. The heightened volatility saw the trading volume jump to 1,390,236 shares. The 52-week high of the share price is $64.3 and the company has a market cap of $2,542 million. The 52-week low of the share price is at $38.41 .
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of cancer immunotherapy products. The Company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Kite Pharma, Inc. is headquartered in Santa Monica, California.